Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LYN00101 in Advanced Solid Tumors
NCT03644459Phase 1Withdrawn
- Sponsor
- Lynkcell
- Start
- Apr 2019
- Primary completion
- Jun 2020
- Modality
- Monoclonal Antibodies
01
Overview
Phase 1, open-label, single-arm trial of LYN-00101 in ovarian cancer, Cervical Cancer (CC), colorectal cancer (CRC) and 1 more, sponsored by Lynkcell. Primary endpoints: Area under the concentration-time curve up to 24 weeks, Peak plasma concentration up to 24 weeks and 6 more. Planned start Apr 2019; status: withdrawn.
02
Drugs
LYN-00101
03
Conditions
ovarian cancerCervical Cancer (CC)colorectal cancer (CRC)gastric cancer (GC)
Beyond the preview
Go deeper on NCT03644459.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03644459.